Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20958440 | 1.00 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL12093367 | 0.87 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL20958365 | 0.86 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL20958333 | 0.86 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL910875 | 0.82 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL910876 | 0.82 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL912055 | 0.80 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL912053 | 0.80 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL20958428 | 0.80 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3EPHX2 | |
| Trifluoroacetic Acid SCHEMBL20958432 | 0.80 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-12-15 | — | — | US | disclosed |
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | NAAA, FAAH, FAAH2 | SLC6A4 2740/4885SLC6A2 2292/4885SLC6A3 2457/4885 |
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | NAAA, FAAH2, FAAH | SLC6A4 3487/4885SLC6A2 3106/4885SLC6A3 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.